**Supplementary Table 4. Low densities** a **of FoxP3+ and CD3+ TILs, and their combination, to predict disease-free survival (DFS) in stage II MSS CRC Validation set**.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | Rate of recurrence (%) | |  | HR (95%CI) b | p |
|  |  |  |  |  |
| **FoxP3+ TILs** | high | 5/87 | (5.8) |  | 1.00, ref. |  |
|  | low | 21/74 | (28.4) |  | 5.15 (1.94-13.7) | .001 |
|  |  |  |  |  |  |  |
| **CD3+ TILs** | high | 9/93 | (9.7) |  | 1.00, ref. |  |
|  | low | 17/68 | (25.0) |  | 2.78 (1.23-6.28) | .001 |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| **FoxP3+/CD3+ TILs** | high/high | 2/54 | (3.7) |  | 1.00, ref. |  |
|  | high/low | 3/33 | (9.1) |  | 3.11 (0.52-18.6) | .21 |
|  | low/high | 7/39 | (18.0) |  | 5.61 (1.16-27.0) | .03 |
|  | low/low | 14/35 | (40.0) |  | 15.2 (3.43-66.9) | <.001 |
|  |  |  |  |  |  |  |
| a defined by optimal cutoffs at ROC curves (Figure 2): 0.23% IRA for Fox P3+ cells, 1.86% IRA for CD3+ cells b multivariate Cox regression analysis,adjusted by tumor local invasion (pT). HR values are for recurrence risk  recurrence risk | | | | | | |